asa guidelines semaglutide 2024 Guideline for the Primary Prevention of Stroke: A Guideline From the American Heart Association/American Stroke Association 2025 ADS/ANZCA/GESA/NACOS clinical practice recommendations

"We will establish a new division focused on obesity and launch Mankind Nutrition, with a separate dedicated field force to lead marketing and engagement for this business," said Rajeev Juneja, managing director, Mankind Pharma

Bu T et al

Kidney Protection Semaglutide also offers protection for the kidneys

The color you see should match what the label describes

baseline in murine studies 60+ Publications On triple-agonist receptor compounds +31% Energy Expenditure Resting metabolic rate increase in models 28% Visceral Fat Intra-abdominal adipose reduction observed Mechanism of Action How GLP-3 (RT) Works Triple-receptor agonism the next generation of metabolic research GLP-1 Primary Glucagon-Like Peptide-1 Incretin hormone receptor activation Suppresses appetite via hypothalamic signaling Delays gastric emptying increases satiety Stimulates glucose-dependent insulin secretion GIP Co-agonist Glucose-Dependent Insulinotropic Polypeptide Adipose tissue and beta-cell modulation Enhances GLP-1 receptor potency synergistically Modulates fat cell lipid uptake and storage Supports pancreatic beta-cell preservation Glucagon Thermogenic Glucagon Receptor Component Hepatic glucose and energy expenditure Increases hepatic glucose output regulation Promotes brown adipose thermogenesis Elevates resting energy expenditure Research Applications Primary Research Areas Obesity & Adiposity Models Studied in diet-induced obesity (DIO) rodent models demonstrating significant reductions in body weight, fat mass, and food intake compared to single-agonist controls

Mundil, D., Cameron-Vendrig, A